Posted 5 мая 2021, 13:53

Published 5 мая 2021, 13:53

Modified 24 декабря 2022, 22:37

Updated 24 декабря 2022, 22:37

Center "Vector" conducts trials of the three-time introduction of "EpiVacCorona" vaccine

Center "Vector" conducts trials of the three-time introduction of "EpiVacCorona" vaccine

5 мая 2021, 13:53
Сюжет
Medicine
The Research Center "Vector" of Rospotrebnadzor is conducting trials to increase the effectiveness of the anti-coronavirus vaccine, which was developed in this center, due to its three-fold administration.

This was announced by the head of the department of zoonotic infections of the State Research Center "Vector" of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare Alexander Ryzhikov.

Previously, three doses of the vaccine have been tested in primates, hamsters and guinea pigs. The number of antibodies increased in their bodies.

"We have already tested triple vaccination on animals. The effect of the increase and duration of immunity was susceptible. Now we are conducting the first and second phases of clinical trials", - he said on the air. the page of the official account of Rospotrebnadzor on Instagram.

Ryzhkov added that a vaccination given three times raises the level of neutralizing antibodies and provides a high affinity (strength of interaction) of these antibodies.

The vaccine of the "Vector" center is the second vaccine against COVID-19 developed in Russia. It was registered last October. In winter, her clinical trials were completed. Now Russians are being vaccinated against coronavirus with this drug.

Volunteers who previously tested this vaccine questioned its effectiveness. According to them, only 70% of those vaccinated (adjusted for placebo) developed antibodies. And even those who had antibodies subsequently contracted the coronavirus . Volunteers sent a letter to the Ministry of Health with a request to check the effectiveness of the drug.

Subscribe